We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00193102
First Posted: September 19, 2005
Last Update Posted: May 3, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Celgene Corporation
Information provided by:
SCRI Development Innovations, LLC
  Purpose
The lack of non-overlapping toxicities between the two drugs, the ease of all oral drug administration, and the possibility for antitumor synergy make exploration of this combination regimen attractive in women with previously treated metastatic breast cancer. This phase II trial will be performed in collaboration with the Minnie Pearl Cancer Research Network, a multicenter, community-based clinical trials group.

Condition Intervention Phase
Breast Cancer Drug: Thalidomide Drug: Capecitabine Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by SCRI Development Innovations, LLC:

Primary Outcome Measures:
  • Overall response rate [ Time Frame: 18 Months ]

Estimated Enrollment: 40
Study Start Date: April 2001
Study Completion Date: June 2010
Primary Completion Date: February 2005 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Thalidomide
    Thalidomide
    Drug: Capecitabine
    Capecitabine
Detailed Description:

Upon determination of eligibility, patients will be receive:

Thalidomide + Capecitebine

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To be included in this study, you must meet the following criteria:

  • Metastatic breast cancer confirmed by biopsy
  • Measurable or evaluable disease
  • Females > 18 years
  • Able to perform activities of daily living with minimal assistance
  • Life expectancy > 3 months
  • Adequate bone marrow, liver and kidney function
  • All patients must give written informed consent in order to participate.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

  • Women who are pregnant or lactating.
  • Received more than 3 prior chemotherapy regimens in the metastatic setting.
  • Received continuous infusion 5-fluorouracil lasting > 120 hours.
  • Received thalidomide or capecitabine as their last prior regimen.
  • Preexisting moderate to severe neuropathy

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00193102


Sponsors and Collaborators
SCRI Development Innovations, LLC
Celgene Corporation
Investigators
Principal Investigator: Howard Burris, MD SCRI Development Innovations, LLC
  More Information

Additional Information:
Publications:
Responsible Party: SCRI Oncology Research Consortium, SCRI
ClinicalTrials.gov Identifier: NCT00193102     History of Changes
Other Study ID Numbers: SCRI BRE 60
First Submitted: September 12, 2005
First Posted: September 19, 2005
Last Update Posted: May 3, 2011
Last Verified: May 2011

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Capecitabine
Thalidomide
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors